Vimta Labs Ltd Stock Price Today (NSE: VIMTALABS)
Vimta Labs Ltd
Fundamental Score
Vimta Labs Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Vimta Labs Ltd share price today is ₹543.85, up +1.26% on NSE/BSE as of 17 June 2026. Vimta Labs Ltd (VIMTALABS) is a Small-cap company in the Healthcare Research, Analytics & Technology sector with a market capitalisation of ₹2.72K (Cr). The 52-week high for VIMTALABS share price is ₹902.65 and the 52-week low is ₹376.05. At a P/E ratio of 36.39x, VIMTALABS is currently trading below its industry average P/E of 45.95x. The company has a Return on Equity (ROE) of 19.43% and a debt-to-equity ratio of 0.02.
Vimta Labs Ltd Share Price Chart — NSE/BSE Historical Performance
Vimta Labs Ltd share price chart: -1.49% return over the past month. 52-week high ₹902.65, 52-week low ₹376.05.
Vimta Labs Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹456.00 | ₹472.00 | ₹451.55 | ₹469.70 | 81.80K (Cr) | |
| ₹474.00 | ₹478.50 | ₹456.40 | ₹462.15 | 1.23L (Cr) | |
| ₹457.05 | ₹485.00 | ₹456.05 | ₹469.70 | 3.06L (Cr) | |
| ₹456.70 | ₹456.70 | ₹456.70 | ₹456.70 | 0.00 (Cr) | |
| ₹465.00 | ₹465.00 | ₹455.00 | ₹456.70 | 65.96K (Cr) | |
| ₹465.00 | ₹472.00 | ₹459.30 | ₹462.35 | 1.05L (Cr) | |
| ₹455.00 | ₹463.40 | ₹454.20 | ₹459.30 | 1.07L (Cr) | |
| ₹453.50 | ₹456.25 | ₹447.55 | ₹451.55 | 78.47K (Cr) | |
| ₹452.00 | ₹457.70 | ₹448.35 | ₹450.30 | 1.07L (Cr) | |
| ₹450.00 | ₹453.05 | ₹443.55 | ₹449.80 | 99.40K (Cr) |
Vimta Labs Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹474.00 | ₹478.50 | ₹451.55 | ₹469.70 | -0.91% | |
| ₹463.30 | ₹579.40 | ₹435.85 | ₹469.70 | +1.38% | |
| ₹397.00 | ₹489.90 | ₹391.80 | ₹457.15 | +15.15% | |
| ₹426.85 | ₹460.00 | ₹376.05 | ₹380.70 | -10.81% | |
| ₹442.00 | ₹511.80 | ₹418.80 | ₹452.05 | +2.27% | |
| ₹605.30 | ₹636.75 | ₹408.10 | ₹411.05 | -32.09% | |
| ₹613.00 | ₹648.95 | ₹577.00 | ₹605.30 | -1.26% | |
| ₹727.40 | ₹735.00 | ₹593.70 | ₹609.05 | -16.27% | |
| ₹711.80 | ₹774.70 | ₹661.80 | ₹725.40 | +1.91% | |
| ₹667.10 | ₹902.65 | ₹648.25 | ₹706.50 | +5.91% | |
| ₹702.00 | ₹728.45 | ₹602.15 | ₹666.25 | -5.09% | |
| ₹449.70 | ₹721.50 | ₹442.85 | ₹693.45 | +54.20% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Vimta Labs Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Vimta Labs Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of VIMTALABS across key market metrics for learning purposes.
Positive Indicators
12 factors identified
Strong Return on Equity (19.43%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (25.22%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (30.85%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 36.39 vs Industry: 45.95)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Strong Revenue Growth (20.19%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (13.74% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (57.82% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (58.03% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.02)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (59.75x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹65.94 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Limited Institutional Interest (FII+DII: 5.20%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Vimta Labs Ltd vs Healthcare Research, Analytics & Technology Peers
Peer Comparison - Healthcare Research, Analytics & Technology
Compare Vimta Labs Ltd with 8 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Vimta Labs LtdVimta Labs Ltd...Selected✓ VIMTALABS • 524394 | 65.8/100 | ₹543.85₹544 | ₹2716.50₹2716.50 | 36.39Average 36.4 Average | 19.43%Good 19.43% Good | 25.22%Excellent 25.22% Excellent | 0.02Excellent 0.0 Excellent | 58.03%Excellent 58.03% Excellent | 13.74%Good 13.74% Good | 0.16% |
Syngene International LtdSyngene Interna... SYNGENE • 539268 | 41.6/100 | ₹460.40₹460 | ₹25985.68₹25985.68 | 55.50Average 55.5 Average | 10.53%Average 10.53% Average | 13.52%Average 13.52% Average | 0.12Excellent 0.1 Excellent | 5.71%Good 5.71% Good | 12.60%Good 12.60% Good | 0.19% |
Indegene LtdIndegene Ltd... INDGN • 544172 | 66.8/100 | ₹518.90₹519 | ₹12660.10₹12660.10 | 28.40Average 28.4 Average | 20.59%Excellent 20.59% Excellent | 24.80%Excellent 24.80% Excellent | 0.04Excellent 0.0 Excellent | 67.93%Excellent 67.93% Excellent | 34.59%Excellent 34.59% Excellent | 0.38% |
Suven Life Sciences LtdSuven Life Scie... SUVEN • 530239 | 6.5/100 | ₹267.15₹267 | ₹3927.58₹3927.58 | — — | -87.22%Poor -87.22% Poor | -86.96%Poor -86.96% Poor | 0.00Excellent 0.0 Excellent | -24.19%Poor -24.19% Poor | -12.00%Poor -12.00% Poor | 0.00% |
Take Solutions LtdTake Solutions ... TAKE • 532890 | 19.5/100 | ₹30.93₹31 | ₹481.24₹481.24 | 120.61Average 120.6 Average | 644.12%Excellent 644.12% Excellent | 11.24%Average 11.24% Average | 0.00Excellent 0.0 Excellent | 38.14%Excellent 38.14% Excellent | — — | 0.00% |
Bilcare LtdBilcare Ltd... BI • 526853 | 6.9/100 | ₹62.20₹62 | ₹200.42₹200.42 | — — | -5.58%Poor -5.58% Poor | 1.10%Poor 1.10% Poor | 1.48Average 1.5 Average | 13.81%Good 13.81% Good | -15.48%Poor -15.48% Poor | 0.00% |
NOVELIX PHARMACEUTICALS LIMITENOVELIX PHARMAC... NOVELIX • 536565 | 40.6/100 | ₹57.14₹57 | ₹101.70₹101.70 | 104.85Average 104.8 Average | 0.64%Poor 0.64% Poor | 0.96%Poor 0.96% Poor | 0.00Excellent 0.0 Excellent | -2.33%Poor -2.33% Poor | 82.92%Excellent 82.92% Excellent | 0.00% |
Adeshwar Meditex LtdAdeshwar Medite... ADESHWAR • 543309 | 29.2/100 | ₹18.41₹18 | ₹25.54₹25.54 | 12.34Average 12.3 Average | 5.51%Poor 5.51% Poor | 8.27%Poor 8.27% Poor | 0.16Excellent 0.2 Excellent | -1.36%Poor -1.36% Poor | 8.33%Good 8.33% Good | 0.00% |
Vanta Bioscience LtdVanta Bioscienc... VANTABIO • 540729 | 7.2/100 | ₹24.45₹24 | ₹16.84₹16.84 | — — | -37.24%Poor -37.24% Poor | -11.58%Poor -11.58% Poor | 1.59Average 1.6 Average | — — | -32.27%Poor -32.27% Poor | 0.00% |
Top Healthcare Research, Analytics & Technology Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Syngene International Ltd share price25985.68 Cr
- Indegene Ltd share price12660.10 Cr
- Suven Life Sciences Ltd share price3927.58 Cr
- Take Solutions Ltd share price481.24 Cr
- Bilcare Ltd share price200.42 Cr
Vimta Labs Ltd PE Ratio History
Historical price-to-earnings ratio for VIMTALABS — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹14.93 | ₹605.30 | 40.5x |
| FY 2024 | ₹9.12 | ₹497.07 | 54.5x |
| FY 2023 | ₹10.68 | ₹201.78 | 18.9x |
| FY 2022 | ₹9.16 | ₹218.20 | 23.8x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Vimta Labs Ltd Dividend History
Annual cash dividends paid by VIMTALABS — dividend yield 0.16%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹4.43 Cr |
| FY 2024 | ₹4.43 Cr |
| FY 2023 | ₹4.42 Cr |
| FY 2022 | ₹4.42 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Vimta Labs Ltd Quarterly Performance
Latest quarterly metrics for VIMTALABS — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
20.19%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
17.04%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
13.74%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
58.03%
Compounded annual net profit growth over 5 years
Vimta Labs Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for VIMTALABS — calculated from daily price history
Selling pressure is heavy — potential reversal zone.
Technical indicators are for educational purposes only. Not investment advice.
Vimta Labs Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Vimta Labs Ltd (VIMTALABS) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Vimta Labs Ltd
About VIMTALABS (Vimta Labs Ltd)
Vimta Labs Ltd is a pioneering force within the healthcare research, analytics, and technology landscape, providing a comprehensive suite of services that underpin the advancement ...of medical science and patient care. The company distinguishes itself through its commitment to rigorous scientific methodology, cutting-edge technologies, and a team of highly skilled professionals dedicated to driving innovation. From meticulously designed preclinical studies to expertly managed clinical trials and sophisticated analytical investigations, Vimta Labs serves as a strategic partner for biopharmaceutical companies, medical device manufacturers, and organizations navigating the complexities of healthcare product development. Its focus extends to ensuring the safety and efficacy of healthcare products, empowering its clients to bring innovative solutions to market with confidence. The capabilities of Vimta Labs span the entire healthcare product lifecycle, encompassing early-stage research, clinical development, and post-market surveillance. Employing advanced technologies in genomics, proteomics, and bioinformatics, the company extracts meaningful insights from complex data, accelerating drug discovery and personalized medicine approaches. Their analytical prowess extends to comprehensive quality control and regulatory compliance, helping clients to navigate the intricate web of industry regulations. By combining deep scientific expertise with sophisticated analytical tools, Vimta Labs contributes to informed decision-making, optimized product development strategies, and improved patient outcomes. Its commitment to rigorous testing and insightful data analysis makes it a valuable partner for businesses seeking to ensure the success of their healthcare products. Beyond traditional laboratory services, Vimta Labs embraces technological advancements to enhance its capabilities and deliver integrated solutions. The company leverages sophisticated data analytics platforms, artificial intelligence, and machine learning algorithms to extract valuable insights from large datasets, accelerating research and optimizing clinical trial design. By seamlessly integrating technology with its scientific expertise, Vimta Labs fosters innovation, drives efficiency, and provides its clients with a competitive edge. With a steadfast dedication to scientific excellence, technological innovation, and client satisfaction, Vimta Labs continues to be a trusted partner for companies seeking to transform healthcare through research, analytics, and advanced technology.
Company Details
Key Leadership
Corporate Events
VIMTALABS Share Price: Frequently Asked Questions
What is the current share price of Vimta Labs Ltd?
Vimta Labs Ltd (VIMTALABS) trades at ₹543.85 on NSE and BSE. Market cap ₹2.72K (Cr). Educational data only.
What is the P/E ratio of Vimta Labs Ltd?
Vimta Labs Ltd has a P/E of 36.39x vs industry average 45.95x.
What is the Bull Run score for Vimta Labs Ltd?
Vimta Labs Ltd has a Bull Run score of 65.8/100 based on 25+ financial parameters.
Does Vimta Labs Ltd pay dividends?
Vimta Labs Ltd has a dividend yield of 0.16%. Past dividends don't guarantee future payments.
What is the ROE of Vimta Labs Ltd?
Vimta Labs Ltd has ROE of 19.43%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Vimta Labs Ltd?
Vimta Labs Ltd has debt-to-equity of 0.02.
Is Vimta Labs Ltd a good investment?
Bull Run gives Vimta Labs Ltd a score of 65.8/100. This is not investment advice — consult a SEBI-registered advisor.